Ventripoint Doubles the Size of Private Placement Due to Strong Investor Demand

Executive Summary

• Ventripoint Diagnostics Ltd. announced it will double its previously disclosed non‑brokered private placement from $500,000 to $1,000,000, pending TSX Venture Exchange approval.
• Each unit consists of one common share and one warrant exercisable at $0.13 per share for 24 months; the company may also issue finder’s warrants up to 8% of gross proceeds.
• Proceeds will be used to fund commercialization activities, manufacturing scale‑up, regulatory submissions, and other operational requirements.

Key Details

• Offering Size: Increased to $1,000,000 (from $500,000).
• Unit Composition: 1 common share + 1 common share purchase warrant.
• Warrant Terms: Exercise price $0.13 per share; valid for 24 months from closing.
• Accelerated Expiry Clause: Company may accelerate expiry with 30‑day notice if the share price trades at $0.26 or above for ten consecutive days.
• Finder’s Warrants: Up to 8% of gross proceeds may be issued as additional warrants, each exercisable at $0.13 per share for 24 months.
• Use of Proceeds: Support critical commercialization activities, manufacturing scale‑up, continued regulatory submissions, and operational requirements.
• Holding Period: All securities subject to a lock‑up of four months plus one day from the closing date.
• Regulatory Notes: Offering not registered under U.S. Securities Act; cannot be offered or sold in the United States absent registration or exemption.

Notable Quotes

(No direct quotes were provided in the release.)